JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB137524

Anti-CYLD antibody

3

(2 Reviews)

|

(19 Publications)

Rabbit Polyclonal CYLD antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 19 publications. Immunogen corresponding to Synthetic Peptide within Human CYLD aa 850-950.

View Alternative Names

CYLD1, KIAA0849, HSPC057, CYLD, Ubiquitin carboxyl-terminal hydrolase CYLD, Deubiquitinating enzyme CYLD, Ubiquitin thioesterase CYLD, Ubiquitin-specific-processing protease CYLD

4 Images
Western blot - Anti-CYLD antibody (AB137524)
  • WB

Supplier Data

Western blot - Anti-CYLD antibody (AB137524)

Samples were separated by 7.5% SDS-PAGE.

All lanes:

Western blot - Anti-CYLD antibody (ab137524) at 1/1000 dilution

Lane 1:

293T whole cell lysates at 30 µg

Lane 2:

A431 whole cell lysates at 30 µg

Lane 3:

HeLa whole cell lysates at 30 µg

Lane 4:

HepG2 whole cell lysates at 30 µg

Secondary

All lanes:

HRP conjugated anti rabbit IgG antibody

Predicted band size: 107 kDa

false

Western blot - Anti-CYLD antibody (AB137524)
  • WB

Supplier Data

Western blot - Anti-CYLD antibody (AB137524)

Samples were separated by 7.5% SDS-PAGE.

All lanes:

Western blot - Anti-CYLD antibody (ab137524) at 1/1000 dilution

Lane 1:

293T whole cell lysates at 30 µg

Lane 2:

A431 whole cell lysates at 30 µg

Secondary

All lanes:

HRP conjugated anti rabbit IgG antibody

Predicted band size: 107 kDa

false

Western blot - Anti-CYLD antibody (AB137524)
  • WB

Supplier Data

Western blot - Anti-CYLD antibody (AB137524)

7.5% SDS-PAGE

All lanes:

Western blot - Anti-CYLD antibody (ab137524) at 1/500 dilution

All lanes:

Rat brain lysate at 50 µg

Predicted band size: 107 kDa

false

Western blot - Anti-CYLD antibody (AB137524)
  • WB

Supplier Data

Western blot - Anti-CYLD antibody (AB137524)

Samples were separated by 7.5% SDS-PAGE.

All lanes:

Western blot - Anti-CYLD antibody (ab137524) at 1/1000 dilution

Lane 1:

Neuro2A whole cell lysates at 30 µg

Lane 2:

NIH 3T3 whole cell lysates at 30 µg

Lane 3:

Raw264.7 whole cell lysates at 30 µg

Lane 4:

C2C12 whole cell lysates at 30 µg

Secondary

All lanes:

HRP conjugated anti rabbit IgG antibody

Predicted band size: 107 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Human CYLD aa 850-950. The exact immunogen used to generate this antibody is proprietary information.

Q9NQC7

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" }, "Cow": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Xenopus tropicalis": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: PBS, 20% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CYLD also known as cylindromatosis or turban tumor syndrome is a protein that serves mainly as a deubiquitinating enzyme. This protein has a mass of approximately 108 kDa and is expressed in a variety of tissues most notably the skin and lungs. It is a negative regulator of cell signaling cascades particularly in pathways where ubiquitination needs to be controlled. CYLD interacts directly with other proteins to remove ubiquitin chains a process that is essential for regulating the degradation of proteins and maintaining cellular functions.
Biological function summary

The deubiquitination activity of CYLD plays a critical role in controlling inflammation and cell proliferation. This protein often associates with complexes that regulate the activity of NF-kB signaling pathways. By removing ubiquitin from specific substrates CYLD limits the activation of NF-kB therefore modulating inflammatory responses in the body. Additionally CYLD's role extends to controlling cell cycle progression and preventing uncontrolled cell growth making it essential in tissue homeostasis.

Pathways

CYLD is a significant regulator of the NF-kB and Wnt signaling pathways. It interacts with proteins such as TRAF2 TRAF6 and NEMO which are important in these pathways. CYLD prevents constitutive activation of NF-kB therefore serving as a checkpoint in inflammation and immune response. In the Wnt signaling pathway CYLD's regulation affects the turnover of beta-catenin highlighting its role in developmental processes and cellular differentiation.

CYLD is closely associated with cylindromatosis and familial adenomatous polyposis. Mutations or disruptions in CYLD function can lead to these conditions where abnormal cell proliferation occurs due to unregulated NF-kB activation. In cylindromatosis CYLD mutations result in the benign skin tumors known as cylindromas. Furthermore its connection to proteins like TRAF2 links it to other tumorigenic processes emphasizing CYLD's influence in both inflammatory and proliferative disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-alpha-induced necroptosis (PubMed : 18313383, PubMed : 18636086, PubMed : 26670046, PubMed : 26997266, PubMed : 27458237, PubMed : 27591049, PubMed : 29291351, PubMed : 32185393). Negatively regulates NF-kappa-B activation by deubiquitinating upstream signaling factors (PubMed : 12917689, PubMed : 12917691, PubMed : 32185393). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed : 12917690). Negative regulator of Wnt signaling (PubMed : 20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed : 19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed : 18222923, PubMed : 20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed : 17495026, PubMed : 19893491). Inhibits nuclear translocation of NF-kappa-B (PubMed : 18636086). Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed : 18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells (By similarity). Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane; this process does not depend on NF-kappa-B activation (By similarity). Ability to remove linear ('Met-1'-linked) polyubiquitin chains regulates innate immunity and TNF-alpha-induced necroptosis : recruited to the LUBAC complex via interaction with SPATA2 and restricts linear polyubiquitin formation on target proteins (PubMed : 26670046, PubMed : 26997266, PubMed : 27458237, PubMed : 27591049). Regulates innate immunity by restricting linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed : 26997266). Involved in TNF-alpha-induced necroptosis by removing linear ('Met-1'-linked) polyubiquitin chains from RIPK1, thereby regulating the kinase activity of RIPK1 (By similarity). Negatively regulates intestinal inflammation by removing 'Lys-63' linked polyubiquitin chain of NLRP6, thereby reducing the interaction between NLRP6 and PYCARD/ASC and formation of the NLRP6 inflammasome (By similarity). Removes 'Lys-63' linked polyubiquitin chain of MAP3K7, which inhibits phosphorylation and blocks downstream activation of the JNK-p38 kinase cascades (PubMed : 29291351). Removes also 'Lys-63'-linked polyubiquitin chains of MAP3K1 and MA3P3K3, which inhibit their interaction with MAP2K1 and MAP2K2 (PubMed : 34497368).
See full target information CYLD

Publications (19)

Recent publications for all applications. Explore the full list and refine your search

Diagnostics (Basel, Switzerland) 14: PubMed39125568

2024

An Immunohistochemical Study of MAGE Proteins in Hepatocellular Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Stylianos Tologkos,Vasiliki Papadatou,Achilleas G Mitrakas,Olga Pagonopoulou,Grigorios Tripsianis,Triantafyllos Alexiadis,Christina-Angelika Alexiadi,Antonios-Periklis Panagiotopoulos,Christina Nikolaidou,Maria Lambropoulou

Journal of orthopaedic surgery and research 19:212 PubMed38561786

2024

CYLD alleviates NLRP3 inflammasome-mediated pyroptosis in osteoporosis by deubiquitinating WNK1.

Applications

Unspecified application

Species

Unspecified reactive species

Guiyong Jiang,Yu Cai,Duo Cheng,Hao Wang,Geyang Deng,Dayong Xiang

Cell death & disease 15:95 PubMed38287022

2024

CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yueshuo Li,Chenxing Yang,Longlong Xie,Feng Shi,Min Tang,Xiangjian Luo,Na Liu,Xudong Hu,Yongwei Zhu,Ann M Bode,Qiang Gao,Jian Zhou,Jia Fan,Xuejun Li,Ya Cao

Cell death & disease 15:79 PubMed38246916

2024

CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression.

Applications

Unspecified application

Species

Unspecified reactive species

Yanan Gu,Shiqi Wu,Junjie Fan,Zeji Meng,Guoqiang Gao,Tianjie Liu,Qi Wang,Huayu Xia,Xinyang Wang,Kaijie Wu

Clinical Medicine Insights. Oncology 17:11795549231180832 PubMed37359274

2023

A Tumor Suppressive Role of CYLD as a Novel Potential DUB of Aurora B in Cervical Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yufan Huang,Wei Zhang,Zhihui Yu,Hongkai Su,Bin Zeng,Jinsong Piao,Jing Wang,Juan Wu

Bioengineered 13:10274-10286 PubMed35435104

2022

LncRNA growth arrest specific transcript 5 inhibits the growth of pituitary neuroendocrine tumors via miR-27a-5p/cylindromatosis axis.

Applications

Unspecified application

Species

Unspecified reactive species

Heyuan Wang,Bing Wu,Haotian Wang,Chunyan Jiang,Zhonghui Liu

Frontiers in cardiovascular medicine 8:639476 PubMed35111821

2022

Blockade of the Notch Signaling Pathway Promotes M2 Macrophage Polarization to Suppress Cardiac Fibrosis Remodeling in Mice With Myocardial Infarction.

Applications

Unspecified application

Species

Unspecified reactive species

Zhi Li,Miao Nie,Liming Yu,Dengshun Tao,Qiang Wang,Yuanchen He,Yu Liu,Yuji Zhang,Hongguang Han,Huishan Wang

Journal of biochemical and molecular toxicology 36:e22910 PubMed34927777

2021

SOX4 induces drug resistance of colorectal cancer cells by downregulating CYLD through transcriptional activation of microRNA-17.

Applications

Unspecified application

Species

Unspecified reactive species

Shuang Pan,Dongyan Bao,Yao Li,Dahua Liu,Shuai Quan,Rong Wang

BMC oral health 21:290 PubMed34092220

2021

Expression of deubiquitinases in human gingiva and cultured human gingival fibroblasts.

Applications

Unspecified application

Species

Unspecified reactive species

Yong-Wei Fu,Hong-Zhi Xu

Aging 13:12207-12223 PubMed33952719

2021

Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1.

Applications

Unspecified application

Species

Unspecified reactive species

Jian Pu,Xianjian Wu,Yi Wu,Zesheng Shao,Chunying Luo,Qianli Tang,Jianchu Wang,Huamei Wei,Yuan Lu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com